Home  »  Company  »  Emmessar Biotech  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Emmessar Biotech & Nutrition Ltd.

Mar 31, 2015

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar

1.3 Due to/ from parties are subject to confirmation.

1.4 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.5 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.6 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.7 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure


Mar 31, 2014

Particulars

Year Ended31.3.2014 Year Ended 31.3.2013

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits The Company''s does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

Particulars - for the year ended March 31, 2014

1.3 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar Details of the transactions with above parties

Financial transactions have been carried out in the ordinary course of business and/ or in discharge of contractual obligations

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.7 Value of Imports on CIF Basis

1.8 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.9 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure


Mar 31, 2013

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallowable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are disclosed as unallowable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emissary Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) A.V.Vardharajan - Executive Director ( Worked up to January 2013)

iii) A.V. Saranagaranjan - Brother of A.V. Vardharanjan( Worked up to October 2012)

iv) Vasudevan Raghavan - Son of MSR Ayyangar (Worked up to August 2012)

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognized, as there is uncertainty of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realizable at value stated in ordinary course of business which are at least equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its nonresident shareholders during the current year as well as previous year.


Mar 31, 2012

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts (Net of Payments Made) in respect of Capital Assets NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits

The Company's does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.AII other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognised, as there is uncertanity of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year.

1.7 The Revised Schedule VI has become effective from 1st April 2011 for the preparation of financial statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous Years figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification/ disclosure.

 
Subscribe now to get personal finance updates in your inbox!